Results 181 to 190 of about 10,811 (204)

Access, Fairness and Affordability: Procedural Justice in NICE, Anvisa and Conitec

SSRN Electronic Journal, 2014
Everywhere, health care systems are making hard choices about medicines. These choices are sensitive, controversial and often result in litigation. For example, the recent report in the UK about the drug Tamiflu casts doubt on the efficacy of the treatment and its value for money to the public health system.
Ricardo Perlingeiro, Christopher Newdick
openaire   +1 more source

Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?

Expert Opinion on Therapeutic Patents, 2013
Pharmaceutical manufacturers who seek new markets for expansion are particularly attracted to Brazil given its potential for growth and the expectation that it will be the fifth largest drug market by 2015. Given the significance of Brazil in the marketplace, strong patent protection for pharmaceutical products and processes is critical. In April 2013,
Lisa L, Mueller, Silvia Moreira, Taketsuma Costa   +1 more
openaire   +2 more sources

ANVISA atualiza regras de pesquisa clínica

Brazilian Journal of Periodontology
Isso mesmo, no último dia 2 de dezembro foram publicadas no Diário Oficial da União (DOU) a Resolução1 ANVISA (Agência Nacional de Vigilância Sanitária) nº 945 e a Instrução Normativa2 nº 338, ambas de 29 de novembro de 2024. Na área da Saúde, a busca pelas melhores práticas passa pela disponibilidade de estudos clínicos que assegurem eficácia e ...
openaire   +1 more source

Anvisa intensifica controle de infecção em serviços de saúde

Revista De Saude Publica, 2004
exaly   +2 more sources

Como surgiu a Biblioteca Digital Da Anvisa

2022
Argentina Santos de Sá, Bruna Guedes Martins da Silva, Fernando de Jesus Pereira, Jaqueline Rodrigues de Jesus, Leda Castro Almeida, Tatiane da Conceição Caetano   +5 more
openaire   +1 more source

A regulação do mercado farmacêutico pela ANVISA e CMED

Direito da Saúde Comparado
Resumo A regulação do mercado farmacêutico brasileiro é essencial para garantir o acesso seguro a medicamentos. A Agência Nacional de Vigilância Sanitária (ANVISA) e a Câmara de Regulação do Mercado de Medicamentos (CMED) desempenham papéis centrais no registro e precificação de medicamentos no Brasil.
Clarice Alegre Petramale, Marcus Carvalho Borin, Silvana Marcia Bruschi Kelles   +2 more
openaire   +1 more source

Evaluation of Adverse Events Recorded in FDA/USA and ANVISA/Brazil Databases for the Medical Equipment: Pulmonary Ventilators, Defibrillators, Infusion Pumps, Physiological Monitors and Ultrasonic Scalpels

IFMBE Proceedings, 2022
D Delisle-Rodríguez, Teodiano Bastos-Filho, Bastos-Filho T F   +2 more
exaly  

As agências reguladoras no Brasil e a Anvisa

2021
openaire   +1 more source

Thirteen years of medication alerts issued by the Brazilian Health Regulatory Agency (ANVISA): What is the profile?

Journal of Evaluation in Clinical Practice, 2020
Vitor Costa Ferreira, Gustavo Costa Ferreira, André Oliveira Baldoni   +2 more
exaly  

The responsive aspect of guiding supervision carried out by Anvisa

[Purpose] The article has the scope of analyzing the existence of a responsive model to provide functionality to Anvisa's inspection and punishment, using the double visit criterion, consisting of an initially guiding and corrective inspection, to draw up infraction notices against Micro and Small Companies, except for risk situations incompatible with
openaire   +1 more source